Company Analysis
Sign in

Lakefront Biotherapeutics (LKFT)

Nasdaq: LKFT · Pharmaceutical Preparations · 2800 Mechelen, BE · filing with the SEC since 2007
Full chart Alerts Compare
Grade7.0
◀ Past 6.6● Present 7.7▶ Future 6.6
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

125 patents granted to the 3 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Lakefront Biotherapeutics’s names, not what it holds today.

Patents granted
125
125 utility, 1976 to Dec 31, 2025
Granted in 2025
3
Against 3 in 2024 and 3 in 2023
Applications published
141
2 of them in 2025
Names they are printed under
3
a former name, a subsidiary
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals13
Organic fine chemistry6
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name3 counted
Galapagos NV a former name
BE, as the owner printed on each patent
118 granted
39 published
Galapagos NV a former name
named as the applicant on its applications, in BE. 1 more under the same name are not counted (printed in US)
0 granted
95 published
Galapagos Sasu a subsidiary
FR, as the owner printed on each patent
7 granted
7 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Nov 18, 202512,472,181Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disordersPharmaceuticalsGalapagos NV
Aug 12, 202512,383,544Methods for the treatment of polycystic kidney diseasePharmaceuticalsGalapagos NV
Apr 1, 202512,264,156Compounds and pharmaceutical compositions thereof for the treatment of diseasesPharmaceuticalsGalapagos NV
Aug 20, 202412,065,443Compounds and pharmaceutical compositions thereof for the treatment of diseasesOrganic fine chemistryGalapagos NV
May 21, 202411,987,621Antibodies for IL-17CPharmaceuticalsGalapagos NV
May 7, 202411,975,008Pharmaceutical compositions comprising a JAK inhibitorPharmaceuticalsGalapagos NV
Aug 8, 202311,718,5885-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritisOrganic fine chemistryGalapagos NV
Jun 6, 202311,667,633Salts and pharmaceutical compositions thereof for the treatment of inflammatory disordersPharmaceuticalsGalapagos NV
Jan 31, 202311,564,923Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disordersPharmaceuticalsGalapagos NV
May 31, 202211,345,691Prodrug modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of usePharmaceuticalsGalapagos NV
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Oct 2, 20252025/0304575COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERSPharmaceuticalsGalapagos NV
Mar 6, 20252025/0074978ANTIBODIES FOR IL-17CPharmaceuticalsGalapagos NV
Oct 3, 20242024/0325404TREATMENT OF INFLAMMATORY DISEASESPharmaceuticalsGalapagos NV
Apr 18, 20242024/0124424SOLID FORMS OF (5S)-CYCLOPROPYL-5-[3-[(3S)-4-(3,5-DIFLUOROPHENYL)-3-METHYL-PIPERAZIN-1-YL]-3-OXO-PROPYL]IMIDAZOLIDINE-2,4-DIONEPharmaceuticalsGalapagos NV
Dec 21, 20232023/0406857SALTS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERSPharmaceuticalsGalapagos NV · patent 12,234,235 granted from it
Dec 21, 20232023/0405007COMPOUND FOR USE IN AND METHODS OF TREATMENT OF FIBROTIC DISEASESPharmaceuticalsGalapagos NV
Oct 5, 20232023/0310433COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERSPharmaceuticalsGalapagos NV · patent 12,472,181 granted from it
Aug 10, 20232023/0250124SUBSTANTIALLY PURE CLARITHROMYCIN 9-OXIME AND ITS PREPARATION THEREOFOrganic fine chemistryGalapagos NV
Aug 3, 20232023/0241068COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR USE IN THE TREATMENT OF FIBROTIC DISEASESPharmaceuticalsGalapagos NV
Jun 29, 20232023/0203149TREATMENT OF ATOPIC DERMATITISPharmaceuticalsGalapagos NV
What it applied for, 2024 to 2025: Pharmaceuticals 4.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton LKFT · research, not advice